{"id":"W4391339917","doi":"10.1200/jco.23.02259","title":"Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies","year":2024,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Ottawa Hospital; University of Toronto; University of Calgary; University of Ottawa","funders":"","keywords":"Medicine; Clinical endpoint; Expanded access; Drug; Progression-free survival; Oncology; End point; Surrogate endpoint; Intensive care medicine; Medical physics; Internal medicine; Overall survival; Clinical trial; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01695302,0.0008713084,0.002119552,0.001169882,0.003510582,0.007362162,0.00173238,0.07242013,0.006444896],"category_scores_gemma":[0.07991238,0.0009121926,0.001566045,0.001113641,0.00401088,0.004555266,0.002927316,0.0484671,0.007244623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006198827,"about_ca_system_score_gemma":0.01329822,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01049836,"about_ca_topic_score_gemma":0.02557598,"domain_scores_codex":[0.9873077,0.005363779,0.0015939,0.000879304,0.003344632,0.001510772],"domain_scores_gemma":[0.9454197,0.0368172,0.003262077,0.001497505,0.006997731,0.006005786],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001638891,0.00006233374,0.001923886,0.00005039888,0.00002163606,0.0007607112,0.0001137246,0.0001506879,0.0002376502,0.01517691,0.9676896,0.01364851],"study_design_scores_gemma":[0.0006651594,0.0002744596,0.00592716,0.0006506122,0.00007466882,0.001518112,0.0004595685,0.003429476,0.0007310447,0.07243648,0.9136471,0.0001860384],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0007527174,0.0004732557,0.0003575032,0.9830582,0.007087782,0.00003117757,0.0001771559,0.00003319876,0.008029098],"genre_scores_gemma":[0.00890581,0.0003636949,0.0008901348,0.956946,0.02111332,0.0000906235,0.00009621857,0.00003543081,0.01155863],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.07242013,"threshold_uncertainty_score":0.08965725,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2902808959613531,"score_gpt":0.4476403663145367,"score_spread":0.1573594703531836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}